指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

欧洲临床微生物学与感染病学会急诊科抗菌药物管理指南(获欧洲医院药师协会认可)

European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European association of hospital pharmacists).
指南 / 共识 · Clin Microbiol Infect · 2024-07-17
一句话结论该指南针对急诊科四个抗菌药物管理主题给出推荐,多数基于极低至低确定性证据,为弱推荐或最佳实践声明,实施需结合急诊具体环境调整。

该指南由欧洲临床微生物学与感染病学会召集专家组,通过共识选定四个急诊科抗菌药物管理主题:生物标志物或快速病原检测、血培养、观察等待(不用或延迟抗菌药物)、结构化培养随访计划。对每个主题进行系统评价,纳入随机对照试验和观察性研究,检索时间为2021年5月至2022年3月,2022年4月补充文献,采用GRADE分级评估证据确定性,并通过共识形成推荐,推荐强度分为强或弱。多数推荐基于极低和低确定性证据,导致弱推荐或无证据时的最佳实践声明,实施需结合急诊具体环境调整。

要点

  • 指南聚焦急诊科四个抗菌药物管理主题:生物标志物/快速病原检测、血培养、观察等待、结构化培养随访计划。
  • 血培养推荐聚焦三种常见感染综合征的指征,明确排除脓毒症或脓毒症休克患者。
  • 生物标志物和快速病原检测推荐聚焦经急诊入院的患者启动抗菌药物,未报告对住院期间停药或降阶梯的影响。
  • 多数推荐基于极低和低确定性证据,为弱推荐或无证据时的最佳实践声明。
  • 实施这些推荐需结合急诊科具体环境和条件进行调整。

适用人群与场景

  • 急诊科就诊的患者,用于支持选择适当的抗菌药物使用实践。
  • 血培养推荐聚焦急诊科三种常见感染综合征,明确排除脓毒症或脓毒症休克患者。
  • 观察等待推荐聚焦特定感染综合征,并纳入了初级保健文献。
  • 生物标志物和快速病原检测推荐聚焦经急诊入院的患者启动抗菌药物。

处置流程与药物剂量

  • 生物标志物或快速病原检测:推荐聚焦经急诊入院的患者启动抗菌药物;未报告对住院期间停药或降阶梯的影响,也未报告对医院感染预防控制实践的影响。
  • 血培养:推荐聚焦急诊科三种常见感染综合征的指征,明确排除脓毒症或脓毒症休克患者。
  • 观察等待(即不用抗菌药物并进行某种形式随访):推荐聚焦特定感染综合征,初级保健文献也被纳入。
  • 结构化培养随访计划:推荐针对急诊出院时培养未回报的患者,以改善抗菌药物处方。
  • 实施这些推荐需结合急诊科具体环境和条件进行调整。

研究设计与关键结果

  • 指南由欧洲临床微生物学与感染病学会召集专家组,通过共识选定四个最相关的抗菌药物管理主题。
  • 对每个主题的主要问题进行了系统评价,纳入随机对照试验和观察性研究,同时评估临床结局和与抗菌药物使用相关的管理过程结局。
  • 文献检索于2021年5月至2022年3月进行;2022年4月,专家组成员被正式要求补充初始检索未发现的额外研究。
  • 数据尽可能进行Meta分析,否则进行叙述性总结;证据确定性根据GRADE标准分级;推荐通过共识过程形成,强度分为强或弱。
  • 为支持实施过程,从同一检索中识别了描述实施促进因素/障碍的实施试验或观察性研究,并进行了叙述性总结。
  • 多数推荐基于极低和低确定性证据,导致弱推荐或无证据时的最佳实践声明。
  • 急诊科抗菌药物管理领域缺乏高质量研究,凸显未来研究的需要。

证据类型、等级与局限

  • 证据类型:指南,基于系统评价(纳入随机对照试验和观察性研究),证据确定性采用GRADE分级,推荐强度分为强或弱。
  • 多数推荐基于极低和低确定性证据,导致弱推荐或无证据时的最佳实践声明。
  • 局限:急诊科抗菌药物管理领域缺乏高质量研究;多数推荐基于极低和低确定性证据;实施需结合急诊具体环境调整。

对床旁实践的改变

  • 该指南为急诊科抗菌药物管理提供基于证据的推荐,但多数推荐为弱推荐或最佳实践声明,实施需结合急诊具体环境和条件调整。
  • 血培养推荐不适用于脓毒症或脓毒症休克患者,指南明确排除该人群。
  • 生物标志物和快速病原检测的推荐仅涉及经急诊入院患者启动抗菌药物,未报告对住院期间停药或降阶梯的影响。
  • 观察等待推荐聚焦特定感染综合征,并纳入了初级保健文献。
  • 结构化培养随访计划推荐针对急诊出院时培养未回报的患者,以改善抗菌药物处方。

指南或共识出处

  • 欧洲临床微生物学与感染病学会急诊科抗菌药物管理指南(获欧洲医院药师协会认可),发表于Clinical Microbiology and Infection。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

SCOPE: This European Society of Clinical Microbiology and Infectious Diseases guideline provides evidence-based recommendations to support a selection of appropriate antibiotic use practices for patients seen in the emergency department (ED) and guidance for their implementation. The topics addressed in this guideline are (a) Do biomarkers or rapid pathogen tests improve antibiotic prescribing and/or clinical outcomes? (b) Does taking blood cultures in common infectious syndromes improve antibiotic prescribing and/or clinical outcomes? (c) Does watchful waiting without antibacterial therapy or with delayed antibiotic prescribing reduce antibiotic prescribing without worsening clinical outcomes in patients with specific infectious syndromes? (d) Do structured culture follow-up programs in patients discharged from the ED with cultures pending improve antibiotic prescribing?

METHODS: An expert panel was convened by European Society of Clinical Microbiology and Infectious Diseases and the guideline chair. The panel selected in consensus the four most relevant antimicrobial stewardship topics according to pre-defined relevance criteria. For each main question for the four topics, a systematic review was performed, including randomized controlled trials and observational studies. Both clinical outcomes and stewardship process outcomes related to antibiotic use were deemed relevant. The literature searches were conducted between May 2021 and March 2022. In April 2022, the panel members were formally asked to suggest additional studies that were not identified in the initial searches. Data were summarized in a meta-analysis if possible or otherwise summarized narratively. The certainty of the evidence was classified according to the Grading of Recommendations Assessment, Development and Evaluation criteria. The guideline panel reviewed the evidence per topic critically appraising the evidence and formulated recommendations through a consensus-based process. The strength of the recommendations was classified as strong or weak. To substantiate the implementation process, implementation trials or observational studies describing facilitators/barriers for implementation were identified from the same searches and were summarized narratively.

RECOMMENDATIONS: The recommendations on the use of biomarkers and rapid pathogen diagnostic tests focus on the initiation of antibiotics in patients admitted through the ED. Their effect on the discontinuation or de-escalation of antibiotics during hospital stay was not reported, neither was their effect on hospital infection prevention and control practices. The recommendations on watchful waiting (i.e. withholding antibiotics with some form of follow-up) focus on specific infectious syndromes for which the primary care literature was also included. The recommendations on blood cultures focus on the indication in three common infectious syndromes in the ED explicitly excluding patients with sepsis or septic shock. Most recommendations are based on very low and low certainty of evidence, leading to weak recommendations or, when no evidence was available, to best practice statements. Implementation of these recommendations needs to be adapted to the specific settings and circumstances of the ED. The scarcity of high-quality studies in the area of antimicrobial stewardship in the ED highlights the need for future research in this field.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

参考来源

  1. Schoffelen T, Papan C, Carrara E, et al. European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European association of hospital pharmacists). Clin Microbiol Infect. 2024. PMID: 39029872. doi:10.1016/j.cmi.2024.05.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。